1. GI clinical research 2002–2003: the year in review
Michael Camilleri 
Clinical Gastroenterology and Hepatology 
Volume 1, Issue 6, Pages (November 2003)
DOI: /S (03)

2. Figure 1
Recurrence of colorectal polyps in patients cured of colorectal cancer. Aspirin (325 mg) reduces the number of polyps relative to placebo, especially the proportion of patients with >1 recurrent adenoma. Data from Sandler et al.3
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )

3. Figure 2
Maintenance of remission in patients with Crohn’s disease treated with infliximab. Note the significant advantage in proportion in clinical remission (CDAI <150) or in clinical response at week 54. Note also that, during 50 weeks of treatment, there is no significant advantage of dose escalation to 10 mg/kg relative to maintaining the same dose at 5 mg/kg. Reproduced with permission from Hanauer et al.10
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )

4. Figure 3
Effect of adefovir dipivoxil on the change in HB virus DNA relative to placebo in patients with chronic hepatitis B virus infection. Reproduced with permission from Hadziyannis et al.16
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )

5. Figure 4
Comparison of the efficacy of peginterferon and interferon with or without ribavirin in patients with chronic hepatitis C virus infection. End-of-treatment and sustained response outcomes show clear advantage of combination of peginterferon with ribavirin compared to the other 2 regimens. Note the remarkable sustained virologic response of 60% in the combination treatment group. Reproduced with permission from Fried et al.18
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )

6. Figure 5
Effect of imatinib on tumor burden in a patient with a gastrointestinal stromal tumor. Reproduced with permission from Demetri et al.20
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )